Prevalence of metabolic syndrome and association with ischemic heart disease in cardiological outpatients;Prevalencia de síndrome metabólico y asociación con la cardiopatía isquémica en pacientes cardiológicos ambulatorios

Revista Clinica Espanola

Volumn 206, Issue 6, 2006, Pages 259-265

  Cordero Fort, A ^a   Moreno Arribas, J ^a   Martin Arnau A ^a   Nasarre Lorite, E ^a   Alegria Barrero E ^a   Alegria Ezquerra E ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Ischemic heart disease; Metabolic syndrome; Prevalence

Indexed keywords

ADULT; AGE; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OUTPATIENT; PREVALENCE; RISK FACTOR;

EID: 33746318420     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13088584     Document Type: Article

References (34)

1. Braunwald E. The Simon Dack lecture. Cardiology: the past, the present, and the future. J Am Coll Cardiol. 2003;42:2031-41.
2. Llácer A, Fernández-Cuenca R. Mortalidad en España en 1999 y 2000 (II). Boletín Epidemiológico Semanal. 2003; 11:121-32.
3. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mähönen M, Cepaitis Z, Kuulasmaa K, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet. 2000;355:688-700.
4. Aranceta J, Pérez C, Serra L, Ribas L, Quiles J, Vioque J, et al. Prevalencia de la obesidad en España: resultados del estudio SEEDO 2000. Med Clin (Barc). 2003;120;608-12.
5. Masiá R, Sala J, Rohlfs I, Piulats R, Manresa MM, Marrugat J. Prevalencia de diabetes mellitus en la provincia de Girona, España: el estudio REGICOR. Rev Esp Cardiol. 2004;57:261-4.
6. Rodríguez-Artalejo F, Guallar-Castellón P, Banegas JR, de Andrés B, del Rey J. La transición de la cardiopatía isquémica aguda a al crónica en España, 1980-1994. Rev Clin Esp. 2001;201:690-5.
7. Howard BV, Cowan LD, Go O, Welty TK, Robbins DC, Lee ET, et al. Adverse effects of diabetes on multiple risk cardiovascular risk factors in women. The Strong Heart Study. Diabetes Care. 1998;21:1258-65.
8. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595-607.
9. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108:1546-51.
10. Alexander CM, Landman PB, Teutsch SM, Haffner SM. NECP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003;52:1210-4.
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
12. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003; 107:391-7.
13. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414-9.
14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9.
15. Meigs JB, Wilson PW, Nathan DM, D'Agostino RB, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes. 2003;52: 2160-7.
16. Álvarez EE, Ribas L, Serra L. Prevalencia del síndrome metabólico en la población de la Comunidad Canaria. Med Clin (Barc). 2003;120:172-4.
17. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Valls J, Carmera R. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J of Intern Med. 2003;14:101-6.
18. Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, Gabriel R, Williams K, Gómez-Gerique JA, et al. Central adiposity determines prevalence differences of the Metabolic syndrome. Obesity Res. 2003; 11:1480-7.
19. Gimeno JA, Lou JM, Molinero E, Poned B, Portilla DP. Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2. Rev Esp Cardiol. 2004;57:507-13.
20. McNeil AM, Rosamond WD, Girman CJ, Heiss G, Hill S, Duncan BB, et al. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (the ARIC study). Am J Cardiol. 2004; 94:1249-54.
21. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Varga S. Effect of increasing metabolic syndrome score on atherosclerosis risk profile and coronary artery disease angiographic severity. Am J Cardiol. 2004;93:159-64.
22. Hernández A, Riera C, Solá E, Oliver MJ, Martínez ML, Morillas C, et al. Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica. Med Clin (Barc). 2003;121:204-8.
23. Corsetti JP, Zareba W, Moss AJ, Ridker PM, Marder VJ, Rainwater DL, et al. Metabolic syndrome best defines the multivariate distribution of blood variables in postinfarction patients. Atherosclerosis. 2003;171:351-8.
24. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53:1195-200.
25. González Juanatey JR, Alegría E, Lozano JV, Llisteri JL, García JM, González I. Impacto de la hipertensión en la cardiopatías en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2001;54:139-49.
26. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA, for conference participants. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109: 551-6.
27. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-9.
28. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio P, Filippucci L, et al. Adeverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension. 2004;43:963-9.
29. Padwal R, Majumdar SR, Johnson JA, Varney J, McAlister FA. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care. 2005;28:735-44.
30. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL The effect of age on the association between body-mass index and mortality. N Engl J Med. 1998;338:1-7.
31. Guallar-Castellón P, Banegas JR, García W, Gutiérrez-Fisac JL, López E, Rodríguez-Artalejo F. Asociación de la enfermedad cardiovascular con el sobrepeso y la obesidad en España. Med Clin (Barc). 2002;118:616-8.
32. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, an all causes in United States adults. Circulation. 2004;110:1245-50.
33. Marroquin OC, Kip HE, Kelley DE, Johnson D, Shaw LJ, Bairey CN, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic Coronary artery disease in women. A report from the Women's Ischemia syndrome evaluation. Circulation. 2004;109:714-21.
34. Bibbins-Domingo K, Lin F, Vittinghoff E, Barret-Connor E, Hulley SB, Grady D, et al. Predictors of heart failure among women with coronary disease. Circulation. 2004;110:1424-30.